During the past decade, Centro de Investigaciones Clínicas Vina del Mar conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 8 clinical trials were completed, i.e. on average, 72.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro de Investigaciones Clínicas Vina del Mar" #1 sponsor was "EMD Serono Research & Development Institute, Inc." with 2 trials, followed by "Takeda" with 2 trials sponsored, "CymaBay Therapeutics, Inc." with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "Galmed Research and Development, Ltd." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro de Investigaciones Clínicas Vina del Mar" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "ClinIntel" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Centro de Investigaciones Clínicas Vina del Mar" are "Carcinoma, Non-Small-Cell Lung" (1 trials), "Early Breast Cancer" (1 trials), "Fatty Liver" (1 trials), "First Line Non-Small Cell Lung Cancer" (1 trials) and "Liver Diseases" (1 trials). Many other conditions were trialed in "Centro de Investigaciones Clínicas Vina del Mar" in a lesser frequency.

Most popular intervention types in "Centro de Investigaciones Clínicas Vina del Mar" are "Drug" (11 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Avelumab" (2 trials), "Aramchol" (1 trials), "Avelumab Weekly" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro de Investigaciones Clínicas Vina del Mar" are 10 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Centro de Investigaciones Clínicas Vina del Mar". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Centro de Investigaciones Clínicas Vina del Mar, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centro de Investigaciones Clínicas Vina del Mar, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".